Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2023.1192526 Oncology Correction Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer Bian Xing 1 2 3 4 Wang Xiaolin 1 2 3 4 Zhang Qiuyan 5 Ma Liying 1 2 3 4 Cao Guozhen 1 2 3 4 Xu Ao 6 7 Han Jinhua 8 Huang Jun 8 Lin Wenchu 1 3 4 * 1 High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China 2 University of Science and Technology of China, Hefei, China 3 Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China 4 High Magnetic Field Laboratory of Anhui Province, Hefei, China 5 The CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences, University of Science and Technology of China, Hefei, China 6 The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China 7 Department of Pathology, Anhui Provincial Hospital, Hefei, China 8 MOE Key Laboratory for Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, China

Edited and Reviewed by: Shiv K. Gupta, Mayo Clinic, United States

*Correspondence: Wenchu Lin, wenchu@hmfl.ac.cn

This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology

 12 04 2023 2023 13 1192526 23 03 2023 27 03 2023 Copyright © 2023 Bian, Wang, Zhang, Ma, Cao, Xu, Han, Huang and Lin 2023 Bian, Wang, Zhang, Ma, Cao, Xu, Han, Huang and Lin

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer by Bian X, Wang X, Zhang Q, Ma L, Cao G, Xu A, Han J, Huang J and Lin W (2020) Front. Oncol. 10:565820. doi: 10.3389/fonc.2020.565820 small cell lung cancer MYC paralog PARP1 BET DNA damage response

Error in Figure/Table

In the published article, there was an error in Figure 3E as published. The representative picture of western blot bands of cleaved PARP1 of H446 cells were presented incorrectly. The corrected Figure 3E and its caption appear below.

The combination effects of JQ1 and BMN673 in SCLC cells. (A–D) CellTiter-Glo Luminescent assays demonstrating the effects of JQ1 and BMN673 as single agents or in combination in MYC paralog-dependent (A), independent (B) SCLC cells, DMS53 cells with c-MYC knockdown (C), and SHP77 cells with c-MYC overexpression (D). A mathematical model was applied to calculate the combination index using the CalcuSyn software program. (E) Western blot analysis of cleaved PARP and MYC paralogs in SCLC cells treated with BMN673 or JQ1 alone or in combination for 24 h. c-MYC for H82, H446 and DMS273, MYCN for H526 and H69, MYCL for H1963. (F), Western blot analysis of cleaved PARP and c-MYC in SHP77 cells with c-MYC overexpression followed by BMN673 and JQ1 treatment alone or in combination for 24 h. GAPDH was used as a loading control. (G) Tumor sphere structures in 3D matrigel were captured under a phase-contrast microscope upon treatment of JQ1 and BMN673 as single agents or in combination for 10 to 15 days. Representative images of tumor spheres were shown in the top panel. Quantification of scored tumor sphere structures (disintegrated, semi-disintegrated, and intact) was shown in the bottom panel. Scale bar, 40 μm. (H) 3D matrigel assays showing the effect of JQ1 and BMN673 in SHP77 cells with or without c-MYC overexpression. 1, Vehicle; 2, BMN673; 3, JQ1; 4, JQ1+BMN673.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.